The demonstration here that persistent VIP expression of CIS43 confers protection up to 36 weeks post-AAV administration (wpa) against a single or sequential malaria challenges provides clear evidence for the promise of this approach for sustaining high levels of antibody. The gene discussed is VIP; the disease is malaria.